Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies
Panelists discuss how challenges in the CAR T referral process include delayed referrals, patient logistics, and managing expectations. One institution addresses these through streamlined communication, patient education, and clear referral guidelines. Community physicians should refer early on, ensure candidacy, and collaborate closely to optimize outcomes.
EP: 1.Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma
EP: 2.Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment
EP: 3.Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?
EP: 4.Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection
EP: 5.CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy
EP: 6.Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers
EP: 7.Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies
EP: 8.Example of Successful Collaboration with a Referring Community Practice
EP: 9.CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways
- What are the most common challenges you have encountered in the CAR-TCAR T referral process, and how have you addressed them at your institution?
- What advice would you provide to community physicians regarding the appropriate timing and preparation for referring patients for CAR-TCAR T-cell therapy?
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
